Retatrutide 5mg/10mg/15mg/20mg/30mg
Brief Introduction:
Retatrutide is an active compound released by Eli Lilly in June 2023. It is a triple (GLP-1/GIP/Gcg) agonist based on the GLP/GI dual receptor agonist Tirzepatide through a hybrid glucagon (GlucagonGcg) related structure, and is a drug for the treatment of obesity and type 2 diabetes. This active compound can activate receptor agonists in our body, which helps control blood sugar and weight loss management.
Sequence:
H-Tyr-Aib-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-α-Me-Leu-Leu-Asp-Lys-{diacid-C20-gamma-Glu-(AEEA)-Lys}-Ala-Gln-Aib-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2
Mechanism of Action:
Retatrutide achieves comprehensive metabolic regulation through triple receptor activation:
※ GLP-1R: Slows gastric emptying, enhances satiety, and reduces appetite.
※ GIPR: Regulates hunger signals in the central nervous system, further suppresses appetite and improves energy metabolism.
※ GCGR: Promotes glucagon secretion, accelerates fat and glycogenolysis, and increases basal metabolic rate.
Video:
Indications and Efficacy:
★ Obesity Treatment:
In the Phase II clinical trial, patients in the highest dose group (12 mg) lost an average of 24.2% weight after 48 weeks, and some patients lost more than 30%.
★ Metabolic Dysfunction-Associated Fatty Liver Disease (MASLD):
Retatrutide can reduce liver fat content by 86%, and more than 85% of patients achieve regression of liver steatosis.
★ Type 2 Diabetes:
Significantly reduce glycated hemoglobin (HbA1c) and improve blood sugar control.
★ Potential Cardiovascular Benefits:
Animal studies have shown that it may indirectly protect cardiovascular health by improving blood pressure and heart function, but further clinical verification is needed.
Market Prospects and Challenges:
◎ Differentiation Advantages:
Compared with existing GLP-1 single-target (such as Semaglutide) or dual-target drugs (such as Tirzepatide), the triple mechanism of retasopeptide has greater potential in weight loss and metabolic improvement.
◎ Cost and Accessibility:
Currently, the production cost of peptide drugs is relatively high, but the long-acting properties of retasopeptide may reduce the frequency of medication and improve patient compliance.
Product Display:
Specifications of our Retatrutide Lyophilized Powder:
| Test Items | Specifications | |
| Appearance | White or almost white powder | |
| Solubility | Freely soluble in water | |
| Water Content (K.F) | Not more than 8.0% | |
| Sodium Salt | Not more than 5.0% | |
| Peptide Purity (HPLC) | Not less than 99.0% | |
| Related Substances (HPLC) | Total impurities | Not more than 2.0% |
| Maximum single impurity | Not more than 1.0% | |
| Peptide Content | Not less than 85.0% | |
| Organic Residual Solvents | Acetonitrile | Not more than 0.041% |
| Dichloromethane | Not more than 0.060% | |
| N, N-Dimethylformamide | Not more than 0.088% | |
| Bacterial Endotoxins | Less than 10 EU/mg | |
| Microbial Limits | TAMC | Not more than 100 CFU/g |
| TYMC | Not more than 100 CFU/g | |
Laboratory & Equipment:
Payment Methods:
Storage Conditions:
Preserved in air tight containers, protected from light.
(Recommended temperature: -25℃ ~ -15℃)
Shelf Life:
24 months from the date of manufacturing when stored under the above conditions.
